Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UBE2K siRNA
- Development stage
- Preclinical
- Lead developer
- Berg
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
UBE2K siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of the UBE2K gene, which encodes the Ubiquitin-conjugating enzyme E2 K. This enzyme is a unique member of the ubiquitin-proteasome system (UPS) involved in protein homeostasis and quality control. In preclinical studies conducted by BERG using their Interrogative Biology platform, UBE2K siRNA was employed to validate UBE2K as a therapeutic target in various cancer models, including pancreatic (MIA PaCa2) and hepatocellular (SKHEP1, HepG2) carcinomas. The siRNA-mediated knockdown of UBE2K results in significant inhibition of cell proliferation, characterized by G2/M cell cycle arrest, stabilization of CyclinB1, and induction of apoptosis. These findings supported the development of small molecule modulators of UBE2K, such as BRG399, for oncology indications.
- Other names
- siRNA mediated knockdown of UBE2KUBE2K-targeting siRNAUBE-2K-targeting siRNAUBE 2K-targeting siRNA
02
Targets
UBE2K (Ubiquitin-conjugating enzyme E2 K)
Beyond the preview
Go deeper on UBE2K siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UBE2K siRNA.